The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday. 
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Principia Biopharma shares jumped to start out the week after it was announced that it would be acquired by Sanofi.
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
GW Pharmaceuticals shares popped early on Monday morning after the company announced that it received a key approval from the FDA for Epidiolex to treat certain seizures.